Clinical Trial Update: Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and pharmacokinetics of DO-2 in adults with advanced solid tumors, including non-small cell lung cancer and hereditary papillary …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Papillary Renal Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• DO-2 (DO-2)

Snippet

Sponsor: DeuterOncology | Conditions: Adult Solid Tumor, Advanced Solid Tumor | Phase 1 | Status: RECRUITING